Top

Avivagen Inc.

TSXV Exchange | Jul 10, 2020, 11:35 AM EDT | Real-time price

VIV $ 0.47 RT
CHANGE
0.00 (0.00%)
VOLUME
0
Day Low: N/A
Day High: N/A
 Back
Avivagen Secures Approval for Use of OxC-beta™ Livestock in Brazil and Signs Distribution Agreement

OTTAWA, Ontario

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”) a life sciences corporation focused on developing and commercializing immune-system improving products for livestock, companion animal and human applications, is pleased to announce that it has received approval from The Ministry of Agriculture-Feed Additives Division for the immediate use of OxC-beta™ Livestock in poultry, swine and cattle (beef and dairy) in Brazil. With regulatory approval secured, Avivagen has also signed a distribution agreement with established São Paulo-based Look Chemicals Importacao E Exportacao LTDA for the use of OxC-beta™ Livestock in poultry and swine.

“We are very excited to secure approval for the use of OxC-beta™ Livestock in Brazil, one of the world’s largest livestock feed markets and an important exporter to many key regions worldwide,” says Kym Anthony, Chief Executive Officer, Avivagen. “With a local distribution agreement already in place with well-regarded Look Chemicals we expect to see quick adoption of OxC-beta™ Livestock in the South American market, with Brazil becoming an important part of Avivagen’s continued growth worldwide.”

Brazil is the world’s third largest production market, producing 69mm tonnes of livestock feed each year, and a key exporter to regions such as Europe that have previously implemented bans against the use of antibiotics in livestock feedi. With the addition of regulatory approval in Brazil, OxC-beta™ Livestock is now approved for use in nine markets worldwide, including the United States, Mexico, New Zealand, Australia, Taiwan, Thailand, Malaysia and the Philippines.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the continued distribution and acceptance of Avivagen’s technology, anticipated adoption of and growth in demand for Avivagen’s products, the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, the size of market opportunities and the potential benefits of the relationship with Look Chemicals are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the regulatory approval may not result in new orders for Avivagen’s products in Brazil, Avivagen’s products may not gain market acceptance or regulatory approval in other new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen, the market opportunities may not be as large as Avivagen anticipates and the anticipated benefits of the Look Chemicals relationship may not be achieved due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


i [i] https://www.alltech.com/press-release/2019-alltech-global-feed-survey-estimates-world-feed-production-increased-3-percent

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.